Dako launches new cancer diagnostic antibodies

Dako has announced the launch of two new ready-to-use antibodies for cancer diagnosis, Anti-CK 8/18 and Anti-TdT.

Anti-CK 8/18 is the first rabbit monoclonal antibody cocktail for cytokeratin 8/18 available from a major pathology provider, helping to classify tumours of unknown origin thanks to its excellent specificity and sensitivity.

Similar benefits will be associated with Anti-TdT, also a rabbit monoclonal antibody, which is used to help classify lymphoma and leukaemia by staining terminal deoxynucleotidyl transferase in tissue samples.

Both antibodies provide optimal staining results enabled by Dako's FLEX Ready-to-Use (RTU) solutions, a plug-and-play solution consisting of pre-diluted antibodies, a visualisation system and optimised validated protocols.

Hans Christian Pedersen, global product manager for IHC reagents at Dako, said: "With the FLEX RTU solution, it takes less time for a lab to validate new antibodies for routine diagnostic use. FLEX Ready-to-Use antibodies are helping labs get high-quality results from day one."

Based in Denmark, the firm is a global leader in tissue-based cancer diagnostics. It became part of Agilent Technologies in 2012.